All News
Filter News
Found 769,185 articles
-
Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"
5/8/2023
Insmed Incorporated today announced progress across its early-stage research programs, which will be discussed in greater detail this morning at the Company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More.
-
ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS
5/8/2023
Endo International plc (OTC: ENDPQ) today reported financial results for the first-quarter ended March 31, 2023.
-
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
5/8/2023
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week ® 2023.
-
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025
5/8/2023
Acasti Pharma Inc. today announced the successful submission to the FDA of GTX-104's full protocol of its pivotal Phase 3 Safety Study and implementation of a strategic realignment plan to maximize shareholder value.
-
TransMedics Group, Inc. Announces Proposed Offering of $300 Million of Convertible Senior Notes Due 2028
5/8/2023
TransMedics Group, Inc. today announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes.
-
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
5/8/2023
CureVac N.V. today announced that the first participant was dosed in the Phase 1 part of a combined Phase 1/2 study of multivalent, modified mRNA seasonal flu vaccine candidates, developed in collaboration with GSK.
-
Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases
5/8/2023
Ginkgo Bioworks today announced a new partnership with Boehringer Ingelheim.
-
Bliss Biopharmaceutical Enters Into a Clinical Trial Collaboration Agreement With an Option of Strategic Collaboration With Eisai for BB-1701
5/8/2023
Bliss Biopharmaceutical Co., Ltd announced a clinical trial collaboration agreement with option for strategic collaboration with Eisai Co., Ltd., for BB-1701, eribulin-payload based ADC directed against Human Epidermal Growth Factor Receptor 2 for the treatment of cancers.
-
INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer
5/8/2023
INmune Bio, Inc. (NASDAQ: INMB) announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for INKmune™, a novel natural killer (NK) cell immunotherapy, for a Phase I/II open-label clinical trial for the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC).
-
Genome Insight Launches in the U.S. with Innovative Whole Genome Sequencing Approach that Offers Unprecedented, Actionable Insights in Cancer Care
5/8/2023
Genome Insight announced today the U.S. launch of CancerVision, their innovative whole genome sequencing (WGS) test designed to provide accurate, timely and medically meaningful insights that collectively guide personalized healthcare decisions.
-
Edwards' Aortic Valve With Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data
5/8/2023
Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration in bioprosthetic aortic valves with the company's innovative RESILIA tissue.
-
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy
5/8/2023
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of a European patent, numbered 3865189, entitled, “Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment.”
-
Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform
5/8/2023
Eyenovia, Inc. (NASDAQ: EYEN) today announced that the U.S. Food and Drug Administration (FDA) has approved Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired.
-
Study Validating ClearNote Health’s Avantect Pancreatic Cancer Detection Test Published in the Journal Clinical Gastroenterology and Hepatology
5/8/2023
ClearNote Health™, a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives, today announced the publication of its analytical validation study for the Avantect™ Pancreatic Cancer Test in Clinical Gastroenterology and Hepatology.
-
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
5/8/2023
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence.
-
Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine
5/8/2023
Innovent Biologics, Inc. announces that second interim analysis and survival analysis results of the ORIENT-31 study have been published in the Lancet Respiratory Medicine.
-
Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023
5/8/2023
Ferring Pharmaceuticals today announced three oral presentations and one poster presentation at Digestive Disease Week® (DDW 2023) for REBYOTA™ (fecal microbiota, live – jslm) a first-in-class single-dose microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
-
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
5/8/2023
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced new data from European researchers that highlight the bioactivity of simufilam on the filamin A (FLNA) protein.
-
Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
5/8/2023
Vedanta Biosciences today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI).
-
SomaLogic opens their first-ever proteomics grant program to APAC life sciences researchers
5/8/2023
SomaLogic, Inc., a global leader in proteomics technology, announced that it is sponsoring the Genomax Research Grant Award for researchers in Singapore.